Evidence map›Paper›PMID 35744887›Full record

ArticleMolecules (Basel, Switzerland)2022

Pyrazolo[4,3-

Karol Bukowski, Beata Marciniak, Mateusz Kciuk, Mariusz Mojzych, Renata Kontek

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Anticancer Activity of Roburic Acid: In Vitro and In Silico Investigation.International journal of molecular sciences · 2025
    Article
  5. Article
  6. Pyrazolo[4,3-International journal of molecular sciences · 2023
    Article
  7. Pyrazolo[4,3-International journal of molecular sciences · 2023
    Article
  8. Genotoxicity of Novel Pyrazolo[4,3-International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Karol BukowskiDepartment of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 12/16 Banacha St., 90-237 Lodz, Poland.ORCID 0000-0003-2517-9898
Beata MarciniakDepartment of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 12/16 Banacha St., 90-237 Lodz, Poland.ORCID 0000-0001-8109-6478
Mateusz KciukDepartment of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 12/16 Banacha St., 90-237 Lodz, Poland.ORCID 0000-0002-8616-3825
Mariusz MojzychDepartment of Chemistry, Siedlce University of Natural Sciences and Humanities, 3 Maja 54, 08-110 Siedlce, Poland.ORCID 0000-0002-9884-6068
Renata KontekDepartment of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 12/16 Banacha St., 90-237 Lodz, Poland.ORCID 0000-0003-2859-9839
University of Łódź · PLUniversity of Siedlce · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper, we present for the first time the evaluation of cytotoxicity and genotoxicity of de novo synthesized pyrazolo[4,3-

Indexed as

Antineoplastic AgentsTriazinesCell Line, TumorComet AssayDNA DamageHumansSulfanilamideSulfonamidesAntineoplastic AgentsSulfanilamideSulfonamidesTriazinesanticancer agentscancer cellscomet assaycytotoxicitygenotoxicityMTTPBMCspyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazinesulfonamidesγ-H2AX

Identifiers

PMID35744887
PMCPMC9229263
OpenAlexW4282548252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.